New hope for HAE patients: extension study tests long-term attack prevention
NCT ID NCT07428499
First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study is for people with hereditary angioedema (HAE) who have already completed a prior phase 3 trial of ADX-324. It aims to see how safe and effective the drug is over a longer period, and whether it can reduce the number of swelling attacks. About 90 adults will receive additional doses of ADX-324, a type of RNA therapy that targets a protein involved in triggering attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ADARx Clinical Site
NOT_YET_RECRUITINGLitchfield Park, Arizona, 85340, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGLittle Rock, Arkansas, 72205, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGSan Diego, California, 92122, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGWalnut Creek, California, 94598, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGOrlando, Florida, 32807, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGChevy Chase, Maryland, 20815, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGWheaton, Maryland, 20902, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGDetroit, Michigan, 48202, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGSt Louis, Missouri, 63141, United States
-
ADARx Clinical Site
RECRUITINGLas Vegas, Nevada, 89128, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGCincinnati, Ohio, 45236, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGColumbus, Ohio, 43235, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGToledo, Ohio, 43617, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGHershey, Pennsylvania, 17033, United States
-
ADARx Clinical Site
NOT_YET_RECRUITINGCapital Federal, Buenos Aires, C1425BEN, Argentina
-
ADARx Clinical Site
NOT_YET_RECRUITINGBuenos Aires, Buenos Aires F.D., C1035AAT, Argentina
-
ADARx Clinical Site
NOT_YET_RECRUITINGAdelaide, South Australia, 5000, Australia
-
ADARx Clinical Site
NOT_YET_RECRUITINGVienna, 1090, Austria
-
ADARx Clinical Site
NOT_YET_RECRUITINGEdegem, Antwerpen, 2650, Belgium
-
ADARx Clinical Site
NOT_YET_RECRUITINGSofia, 1000, Bulgaria
-
ADARx Clinical Site
NOT_YET_RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
-
ADARx Clinical Site
NOT_YET_RECRUITINGOttawa, Ontario, K1H 1E4, Canada
-
ADARx Clinical Site
NOT_YET_RECRUITINGMontreal, Quebec, H2W 1R7, Canada
-
ADARx Clinical Site
NOT_YET_RECRUITINGBeijing, 100730, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGHarbin, 150001, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGZhengzhou, 450003, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGSplit, 21000, Croatia
-
ADARx Clinical Site
NOT_YET_RECRUITINGZagreb, 10000, Croatia
-
ADARx Clinical Site
NOT_YET_RECRUITINGHradec Králové, 500 05, Czechia
-
ADARx Clinical Site
NOT_YET_RECRUITINGPrague, 15000, Czechia
-
ADARx Clinical Site
NOT_YET_RECRUITINGNice, Alpes-Maritimes, 06300, France
-
ADARx Clinical Site
NOT_YET_RECRUITINGTours, Indre-et-Loire, 37000, France
-
ADARx Clinical Site
NOT_YET_RECRUITINGMontpellier, 34295, France
-
ADARx Clinical Site
NOT_YET_RECRUITINGParis, 75012, France
-
ADARx Clinical Site
NOT_YET_RECRUITINGTübingen, Baden-Wurttemberg, 72076, Germany
-
ADARx Clinical Site
NOT_YET_RECRUITINGHong Kong, 111, Hong Kong
-
ADARx Clinical Site
NOT_YET_RECRUITINGBudapest, 1088, Hungary
-
ADARx Clinical Site
NOT_YET_RECRUITINGAshkelon, 7830604, Israel
-
ADARx Clinical Site
NOT_YET_RECRUITINGTel Aviv, 5262100, Israel
-
ADARx Clinical Site
NOT_YET_RECRUITINGLodz, 92-213, Poland
-
ADARx Clinical Site
NOT_YET_RECRUITINGBarcelona, 08907, Spain
-
ADARx Clinical Site
NOT_YET_RECRUITINGMadrid, 28007, Spain
-
ADARx Clinical Site
NOT_YET_RECRUITINGTaichung, 40705, Taiwan
-
ADARx Clinical Site
NOT_YET_RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
ADARx Clinical Site
NOT_YET_RECRUITINGCardiff, CF14 4YS, United Kingdom
-
ADARx Clinical Site
NOT_YET_RECRUITINGLondon, E1 1BB, United Kingdom
-
ADARx Clinical Site
NOT_YET_RECRUITINGSouthampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.